Phytochemicals Attenuating Aberrant Activation of β-Catenin in Cancer Cells

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Wang, Dan ^a   Wise, Mitchell L ^b   Li, Feng ^a   Dey, Moul ^a  

^a SOUTH DAKOTA STATE UNIVERSITY   (United States)

^b U S DEPARTMENT OF AGRICULTURE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; AVENANTHRAMIDE 2P; BETA CATENIN; LITHIUM CHLORIDE; MESSENGER RNA; MYC PROTEIN; TRIPTOLIDE; UNCLASSIFIED DRUG; WNT PROTEIN;

AMINO ACID SEQUENCE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CELL CULTURE; CARCINOGENESIS; CHEMOPROPHYLAXIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; DRUG SCREENING; EMBRYO; HELA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; NUCLEAR LOCALIZATION SIGNAL; NUCLEOTIDE SEQUENCE; OAT; ONCOGENE C MYC; PHYTOCHEMISTRY; PROCESS OPTIMIZATION; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; TRANSCRIPTION INITIATION; UTERINE CERVIX CANCER; WNT SIGNALING PATHWAY;

BETA CATENIN; BLOTTING, WESTERN; FLUORESCENT ANTIBODY TECHNIQUE; HELA CELLS; HUMANS; NEOPLASMS; PLANT EXTRACTS; REAL-TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC; WNT PROTEINS;

AVENA;

EID: 84870702455     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0050508     Document Type: Article

References (49)

1. Clevers H, (2006) Wnt/beta-catenin signaling in development and disease. Cell 127: 469-480.
2. Rahmani M, Read JT, Carthy JM, McDonald PC, Wong BW, et al. (2005) Regulation of the Versican Promoter by the β-Catenin-T-cell Factor Complex in Vascular Smooth Muscle Cells. Journal of Biological Chemistry 280: 13019-13028.
3. Jin T, George Fantus I, Sun J, (2008) Wnt and beyond Wnt: Multiple mechanisms control the transcriptional property of β-catenin. Cellular Signalling 20: 1697-1704.
4. Tarapore RS, Siddiqui IA, Mukhtar H, (2012) Modulation of Wnt/β-catenin signaling pathway by bioactive food components. Carcinogenesis 33: 483-491.
5. Bulut G, Fallen S, Beauchamp EM, Drebing LE, Sun J, et al. (2011) Beta-Catenin Accelerates Human Papilloma Virus Type-16 Mediated Cervical Carcinogenesis in Transgenic Mice. PLoS ONE 6: e27243.
6. Kim JH, Kim B, Cai L, Choi HJ, Ohgi KA, et al. (2005) Transcriptional regulation of a metastasis suppressor gene by Tip60 and beta-catenin complexes. Nature 434: 921-926.
7. Essers MA, de Vries-Smits LM, Barker N, Polderman PE, Burgering BM, et al. (2005) Functional interaction between beta-catenin and FOXO in oxidative stress signaling. Science 308: 1181-1184.
8. Katoh M, Katoh M, (2007) WNT Signaling Pathway and Stem Cell Signaling Network. Clinical Cancer Research 13: 4042-4045.
9. Guo W, Nie L, Wu D, Wise ML, Collins FW, et al. (2010) Avenanthramides Inhibit Proliferation of Human Colon Cancer Cell Lines In Vitro. Nutrition and Cancer 62: 1007-1016.
10. Okazaki Y, Isobe T, Iwata Y, Matsukawa T, Matsuda F, et al. (2004) Metabolism of avenanthramide phytoalexins in oats. Plant J 39: 560-572.
11. Chen CY, Milbury PE, Collins FW, Blumberg JB, (2007) Avenanthramides are bioavailable and have antioxidant activity in humans after acute consumption of an enriched mixture from oats. J Nutr 137: 1375-1382.
12. Nie L, Wise ML, Peterson DM, Meydani M, (2006) Avenanthramide, a polyphenol from oats, inhibits vascular smooth muscle cell proliferation and enhances nitric oxide production. Atherosclerosis 186: 260-266.
13. Ren Y, Yang X, Niu X, Liu S, Ren G, (2011) Chemical characterization of the avenanthramide-rich extract from oat and its effect on D-galactose-induced oxidative stress in mice. J Agric Food Chem 59: 206-211.
14. Sur R, Nigam A, Grote D, Liebel F, Southall MD, (2008) Avenanthramides, polyphenols from oats, exhibit anti-inflammatory and anti-itch activity. Arch Dermatol Res 300: 569-574.
15. Chen CY, Milbury PE, Kwak HK, Collins FW, Samuel P, et al. (2004) Avenanthramides and phenolic acids from oats are bioavailable and act synergistically with vitamin C to enhance hamster and human LDL resistance to oxidation. J Nutr 134: 1459-1466.
16. Koenig RT, Dickman JR, Wise ML, Ji LL, (2011) Avenanthramides are bioavailable and accumulate in hepatic, cardiac, and skeletal muscle tissue following oral gavage in rats. J Agric Food Chem 59: 6438-6443.
17. Guo W, Wise ML, Collins FW, Meydani M, (2008) Avenanthramides, polyphenols from oats, inhibit IL-1beta-induced NF-kappaB activation in endothelial cells. Free Radic Biol Med 44: 415-429.
18. Nishikawa A, Furukawa F, Lee IS, Tanaka T, Hirose M, (2004) Potent Chemopreventive Agents Against Pancreatic Cancer. Current Cancer Drug Targets 4: 373-384.
19. NCI/DCPC (1996) Clinical development plan: phenethyl isothiocyanate. J Cell Biochem Suppl 26: 149-157.
20. Dey M, Kuhn P, Ribnicky D, Premkumar V, Reuhl K, et al. (2010) Dietary phenethylisothiocyanate attenuates bowel inflammation in mice. BMC Chemical Biology 10: 4.
21. Dey M, Ribnicky D, Kurmukov AG, Raskin I, (2006) In Vitro and in Vivo Anti-Inflammatory Activity of a Seed Preparation Containing Phenethylisothiocyanate. Journal of Pharmacology and Experimental Therapeutics 317: 326-333.
22. Wu X, Zhu Y, Yan H, Liu B, Li Y, et al. (2010) Isothiocyanates induce oxidative stress and suppress the metastasis potential of human non-small cell lung cancer cells. BMC Cancer 10: 269.
23. Liu Q, (2011) Triptolide and its expanding multiple pharmacological functions. International Immunopharmacology 11: 377-383.
24. Ma J, Dey M, Yang H, Poulev A, Pouleva R, et al. (2007) Anti-inflammatory and immunosuppressive compounds from Tripterygium wilfordii. Phytochemistry 68: 1172-1178.
25. Premkumar V, Dey M, Dorn R, Raskin I, (2010) MyD88-dependent and independent pathways of Toll-Like Receptors are engaged in biological activity of Triptolide in ligand-stimulated macrophages. BMC Chemical Biology 10: 3.
26. He M-F, Liu L, Ge W, Shaw P-C, Jiang R, et al. (2009) Antiangiogenic activity of Tripterygium wilfordii and its terpenoids. Journal of Ethnopharmacology 121: 61-68.
27. Macville M, Schröck E, Padilla-Nash H, Keck C, Ghadimi BM, et al. (1999) Comprehensive and Definitive Molecular Cytogenetic Characterization of HeLa Cells by Spectral Karyotyping. Cancer Research 59: 141-150.
28. Dang CV, Le A, Gao P, (2009) MYC-Induced Cancer Cell Energy Metabolism and Therapeutic Opportunities. Clinical Cancer Research 15: 6479-6483.
29. Clément-Lacroix P, Ai M, Morvan F, Roman-Roman S, Vayssière B, et al. (2005) Lrp5-independent activation of Wnt signaling by lithium chloride increases bone formation and bone mass in mice. Proceedings of the National Academy of Sciences of the United States of America 102: 17406-17411.
30. Hiyama A, Sakai D, Arai F, Nakajima D, Yokoyama K, et al. (2011) Effects of a glycogen synthase kinase-3β inhibitor (LiCl) on c-myc protein in intervertebral disc cells. Journal of Cellular Biochemistry 112: 2974-2986.
31. Klein PS, Melton DA, (1996) A molecular mechanism for the effect of lithium on development. Proceedings of the National Academy of Sciences 93: 8455-8459.
32. Handeli S, Simon JA, (2008) A small-molecule inhibitor of Tcf/β-catenin signaling down-regulates PPARγ and PPARδ activities. Molecular Cancer Therapeutics 7: 521-529.
33. Polk WW (2012) FH535 Potentiation of Cigarette Smoke Condensate Cytotoxicity Is Associated With Changes in ss-Catenin and EGR-1 Signaling. Int J Toxicol.
34. Fuerer C, Nusse R, (2010) Lentiviral Vectors to Probe and Manipulate the Wnt Signaling Pathway. PLoS ONE 5: e9370.
35. Stewart SA, Dykxhoorn DM, Palliser D, Mizuno H, Yu EY, et al. (2003) Lentivirus-delivered stable gene silencing by RNAi in primary cells. RNA 9: 493-501.
36. Wise ML, (2011) Effect of chemical systemic acquired resistance elicitors on avenanthramide biosynthesis in oat (Avena sativa). J Agric Food Chem 59: 7028-7038.
37. Wang D, Harmon A, Jin J, Francis DH, Christopher-Hennings J, et al. (2010) The lack of an inherent membrane targeting signal is responsible for the failure of the matrix (M1) protein of influenza A virus to bud into virus-like particles. J Virol 84: 4673-4681.
38. Gao X, Wan F, Mateo K, Callegari E, Wang D, et al. (2009) Bacterial Effector Binding to Ribosomal Protein S3 Subverts NF-κB Function. PLoS Pathog 5: e1000708.
39. Gregory CA, Perry AS, Reyes E, Conley A, Gunn WG, et al. (2005) Dkk-1-derived Synthetic Peptides and Lithium Chloride for the Control and Recovery of Adult Stem Cells from Bone Marrow. Journal of Biological Chemistry 280: 2309-2323.
40. Sokol SY, (2011) Wnt signaling through T-cell factor phosphorylation. Cell Res 21: 1002-1012.
41. Meydani M, (2009) Potential health benefits of avenanthramides of oats. Nutrition Reviews 67: 731-735.
42. Kim MJ, Lee TH, Kim SH, Choi Y-J, Heo J, et al. (2010) Triptolide inactivates Akt and induces caspase-dependent death in cervical cancer cells via the mitochondrial pathway. International Journal of Oncology 37: 1177-1185.
43. Krejci P, Aklian A, Kaucka M, Sevcikova E, Prochazkova J, et al. (2012) Receptor Tyrosine Kinases Activate Canonical WNT/β-Catenin Signaling via MAP Kinase/LRP6 Pathway and Direct β-Catenin Phosphorylation. PLoS ONE 7: e35826.
44. Cairo S, Armengol C, De Reyniès A, Wei Y, Thomas E, et al. (2008) Hepatic Stem-like Phenotype and Interplay of Wnt/β-Catenin and Myc Signaling in Aggressive Childhood Liver Cancer. Cancer Cell 14: 471-484.
45. Shao F, Wang G, Xie H, Zhu X, Sun J, et al. (2007) Pharmacokinetic Study of Triptolide, a Constituent of Immunosuppressive Chinese Herb Medicine, in Rats. Biological and Pharmaceutical Bulletin 30: 702-707.
46. Peterson CW, Ayer DE, (2011) An extended Myc network contributes to glucose homeostasis in cancer and diabetes. Frontiers in Bioscience 16: 2206-2223.
47. Arcidiacono B, Iiritano S, Nocera A, Possidente K, Nevolo MT, et al. (2012) Insulin Resistance and Cancer Risk: An Overview of the Pathogenetic Mechanisms. Experimental Diabetes Research 2012: 12.
48. Antonoff MB, Chugh R, Borja-Cacho D, Dudeja V, Clawson KA, et al. (2009) Triptolide therapy for neuroblastoma decreases cell viability in vitro and inhibits tumor growth in vivo. Surgery 146: 282-290.
49. Kitzen JJEM, de Jonge MJA, Lamers CHJ, Eskens FALM, van der Biessen D, et al. (2009) Phase I dose-escalation study of F60008, a novel apoptosis inducer, in patients with advanced solid tumours. European Journal of Cancer 45: 1764-1772.